A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)

Phase 3

Completed

• Conditions: Depressive Disorder
• Interventions: Drug: Saredutant (SR48968C); Drug: Placebo

• Registration Number: NCT00336713
• Lead Sponsor: Sanofi

Brief Summary

The purpose of the study is to evaluate the long-term efficacy and safety of Saredutant in patients with depression. The primary objective is to evaluate the efficacy and safety of Saredutant 100 mg once daily compared to placebo in the prevention of relapse of depressive symptoms in outpatients with major depressive disorder who achieved an initial response to 12 weeks of open-label treatment with Saredutant.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-05
• Study First Submitted: 2006-06-13
• Study First Submitted QC: 2006-06-13
• Study First Posted: 2006-06-14
• Primary Completion: 2008-04
• Study Completion: 2008-04
• Status Verified: 2016-04
• Disposition First Submitted: 2016-04-13
• Disposition First Submitted QC: 2016-04-13
• Last Update Submitted: 2016-04-13
• Disposition First Posted: 2016-05-13
• Last Update Posted: 2016-05-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 430

Inclusion Criteria

• Diagnosis of major depressive disorder, as defined by Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) criteria and confirmed by the semi-structured Mini International Neuropsychiatric Interview (MINI), recurrent episode.

Read More

Exclusion Criteria

• Total score of 28 or less on the Montgomery and Asberg Depression Rating Scale (MADRS).
• Clinical Global Impression (CGI) severity score of less than 4.
• Duration of the current depressive episode less than 2 months or greater than 2 years.
• Elderly patients with a Mini-Mental State Examination (MMSE) total score <25.
• Patients with a history or presence of bipolar disorders or psychotic disorders.
• Patients with alcohol dependence or abuse or substance dependence or abuse in the past 12 months except nicotine or caffeine dependence.
• Benzodiazepine or sedative-hypnotic use greater than 2 days per week during the month prior to entry into the Acute Phase.
• Patients who have used the following prior to entry into Acute Phase: antipsychotics within 3 months, fluoxetine within 1 month, Monoamine oxidase inhibitors (MAOIs) within 2 weeks, other antidepressant or mood-stabilizer (lithium, anticonvulsants) within 1 week.

The investigator will evaluate whether there are other reasons why a patient may not participate.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Saredutant 100 mg	Saredutant (SR48968C)	Saredutant 100 mg once daily in the morning for a maximum of 64 weeks
Placebo	Placebo	Placebo for Saredutant once daily in the morning during the maintenance phase for a maximum of 52 weeks

Primary Outcome Measures

Name	Time	Method
The time to relapse of depressive symptoms (in days) during the Maintenance Phase.	minimum 24 weeks and maximum 52 weeks

Secondary Outcome Measures

Name	Time	Method
Changes from baseline in the CGI Severity of Illness, Montgomery-Asberg Depression Rating Scale (MADRS) total, and Hamilton Anxiety Rating Scale (HAM-A) total and factor scores during the Maintenance Phase.	minimum 24 weeks and maximum 52 weeks

Trial Locations

Locations (1)

Sanofi-Aventis; 🇺🇸 Bridgewater, New Jersey, United States